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Introduction
The enzymes tryptophan 2,3-dioxygenase (TDO) and
indoleamine 2,3-dioxygenase (IDO1) catalyse oxidation of
the essential amino acid tryptophan (Trp) leading to the
formation of immunosuppressive kynurenine (Kyn) path-
way metabolites that dampen the immune response in the
tumour microenvironment. Both IDO1 and TDO have
been shown to be up-regulated in a variety of cancers and
blockade of their activity has been shown to stimulate the
anti-tumour immune response in pre-clinical animal mod-
els. We have discovered multiple novel chemical series of
both highly selective and dual-acting inhibitors of IDO1
and TDO. Herein we describe their in vitro and in vivo
characterisation.
Methods
In vitro assays measured the effects of TDO/IDO1 inhi-
bitors on Kyn production in cancer cells, hPBMCs and
effects on T cell proliferation in co-culture systems.
In vitro ADME properties and in vivo PK/PD profiles
were measured by standard methods. In the LPS model
of Kyn stimulation, LPS was administered at 5 mg/kg IP
simultaneously with oral administration of IDO1 inhibi-
tors. Plasma and tissue samples were collected 20 hours
after dosing.
Results
We have identified multiple distinct chemical series of
novel IDO1 and TDO inhibitors which demonstrate nM
potencies. In addition, we have also identified dual-
acting TDO and IDO1 inhibitors, exemplars of which
exhibit nM potency at each enzyme. Such dual-acting
molecules are required to fully inhibit Kyn levels in
IFNg-stimulated A172 glioblastoma cells expressing both
enzymes, demonstrating the utility of dual enzyme
blockade in cancer cells. The compounds also relieve
inhibition of T cell proliferation in cancer cell/T cell co-
culture assays and demonstrate highly favourable phy-
sico-chemical and pharmacokinetic properties. These
properties translate to superior PK/PD effects following
oral dosing in rodents with profound and sustained
modulation of plasma Kyn and Trp levels. In a mouse
model of LPS-induced IDO1 activation, our highly selec-
tive IDO1 inhibitors fully ablate the elevation of Kyn in
both plasma and lung tissues in a dose-dependent man-
ner. This lung Kyn modulation is more potent and effi-
cacious than that observed for molecules in clinical
trials.
Conclusions
We describe the characterisation of multiple novel che-
mical series of potent, selective and dual-acting TDO
and IDO1 inhibitors. The drug-like properties of these
potent molecules translate to superior in vivo PK/PD
profiles compared to compounds in clinical trials. This
clear metabolic advantage is expected to translate to a
significantly better PK/PD effect in humans, especially
in lung cancer – a major opportunity for a-PD-1/PD-L1
and IDO1 inhibitor combination therapy.
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